JAMP RASAGILINE TABLET

देश: कनाडा

भाषा: अंग्रेज़ी

स्रोत: Health Canada

इसे खरीदें

सक्रिय संघटक:

RASAGILINE (RASAGILINE MESYLATE)

थमां उपलब्ध:

JAMP PHARMA CORPORATION

ए.टी.सी कोड:

N04BD02

INN (इंटरनेशनल नाम):

RASAGILINE

डोज़:

0.5MG

फार्मास्यूटिकल फॉर्म:

TABLET

रचना:

RASAGILINE (RASAGILINE MESYLATE) 0.5MG

प्रशासन का मार्ग:

ORAL

पैकेज में यूनिट:

15G/50G

प्रिस्क्रिप्शन प्रकार:

Prescription

चिकित्सीय क्षेत्र:

MONOAMINE OXIDASE B INHIBITORS

उत्पाद समीक्षा:

Active ingredient group (AIG) number: 0151662001; AHFS:

प्राधिकरण का दर्जा:

APPROVED

प्राधिकरण की तारीख:

2019-09-06

उत्पाद विशेषताएं

                                PRODUCT MONOGRAPH
PR
JAMP RASAGILINE
(RASAGILINE TABLETS)
0.5 MG AND 1 MG RASAGILINE
(AS RASAGILINE MESYLATE)
ANTIPARKINSON AGENT
JAMP Pharma Corporation
Date of Preparation: September 4, 2019
1310, rue Nobel
Boucherville, Québec
J4B 5H3
Control Number: 224660
_Product Monograph of Jamp Rasagiline_
_Page 2 of 43_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
....................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................10
DRUG INTERACTIONS
..................................................................................................16
DOSAGE AND ADMINISTRATION
..............................................................................18
OVERDOSAGE
.................................................................................................................19
ACTION AND CLINICAL PHARMACOLOGY
.............................................................20
STORAGE AND STABILITY
..........................................................................................23
DOSAGE FORMS, COMPOSITION AND PACKAGING
..............................................23
PART II: SCIENTIFIC INFORMATION
................................................................................24
PHARMACEUTICAL INFORMATION
..........................................................................24
CLINICAL TRIALS
..........................................................................................................25
DETAILED PHARMACOLOGY
....................................
                                
                                पूरा दस्तावेज़ पढ़ें
                                
                            

अन्य भाषाओं में दस्तावेज़

उत्पाद विशेषताएं उत्पाद विशेषताएं फ़्रेंच 04-09-2019

इस उत्पाद से संबंधित अलर्ट देखें

दस्तावेज़ इतिहास देखें